Market Research Logo

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2018

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2018, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 82, 90, 3, 128, 27 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 8, 12, 1, 1, 24 and 5 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Multiple Myeloma (Kahler Disease) - Overview
Multiple Myeloma (Kahler Disease) - Therapeutics Development
Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
Multiple Myeloma (Kahler Disease) - Drug Profiles
Multiple Myeloma (Kahler Disease) - Dormant Projects
Multiple Myeloma (Kahler Disease) - Discontinued Products
Multiple Myeloma (Kahler Disease) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Abpro, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Alissa Pharma, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corp, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences LLC, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Autolus Ltd, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by BioClin Therapeutics Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by BioLineRx Ltd, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Biomunex Pharmaceuticals, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Co, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by CanBas Co Ltd, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by CARsgen Therapeutics Ltd, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Cellestia Biotech AG, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Cellular Biomedicine Group Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by CRISPR Therapeutics, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Dexcel PT Israel Ltd, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Co, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by eTheRNA Immunotherapies NV, H1 2018
Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis Inc, H1 2018
List of Figures
Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report